Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Inv. presentation
CC transcript
Acq. announced
CASTLE BIOSCIENCES INC (CSTL) Create: Alert

All | News | Filings
Date FiledTypeDescription
02/28/2023 8-K Investor presentation, Quarterly results
Docs: "Castle Biosciences Reports Fourth Quarter and Full-Year 2022 Results Full-year 2022 revenue was up 46% over 2021 to $137 million, meeting top end of guided range Delivered 44,419 total test reports in 2022, an increase of 58% compared to 2021",
"137.0 2017 2018 2019 2020 2021 2022 10,614 13,445 17,055 18,185 28,145 44,419 2017 2018 2019 2020 2021 2022"
08/08/2022 8-K Quarterly results
05/09/2022 8-K Quarterly results
02/28/2022 8-K Investor presentation, Quarterly results
Docs: "Castle Biosciences Reports Fourth Quarter and Full-Year 2021 Results Full-year 2021 revenue was up 50% over 2020 to $94.1 million, beating expectations Growth of 55% year over year in total GEP testing volume",
"F O R W A R D"
11/08/2021 8-K Investor presentation, Quarterly results
Docs: "Castle Biosciences Announces Third Quarter 2021 Results Q3 2021 revenue grew by 54% over the prior year quarter to $23.5 million Q3 2021 total dermatology test report volume of 7,352",
"2 0 2 1 A"
08/09/2021 8-K Investor presentation, Quarterly results
Docs: "Castle Biosciences Announces Second Quarter 2021 Results Q2 2021 revenues of $22.8 million, compared to $12.7 million in Q2 2020 Q2 2021 total dermatology test report volume of 6,539",
"F O R W A R D"
05/10/2021 8-K Quarterly results
03/08/2021 8-K Quarterly results
08/10/2020 8-K Quarterly results
05/11/2020 8-K Quarterly results
Docs: "Castle Biosciences Announces First Quarter 2020 Results Q1 2020 DecisionDx-Melanoma test report volume increased 42% compared to Q1 2019"
03/10/2020 8-K Quarterly results
11/12/2019 8-K Quarterly results
09/03/2019 8-K Quarterly results
Docs: "Castle Biosciences Reports Second Quarter 2019 Results • Q2 2019 DecisionDx-Melanoma test report volume increased 27% compared to Q2 2018 • Q2 2019 recognized revenues increased to $10.7 million, up from $4.0 million in Q2 2018 • Q2 2019 gross margin increased to 81%, up from 67% in Q2 2018"

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy